Clinical Trials Logo

Excessive Daytime Somnolence clinical trials

View clinical trials related to Excessive Daytime Somnolence.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05056194 Not yet recruiting - Parkinson Disease Clinical Trials

Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

Following screening visit and verification of inclusion/exclusion criteria and informed consent, participants will undergo a multiple sleep latency test (MSLT) and polysomnogram (PSG) assessments to confirm eligibility for randomization. Participants will be randomized to two groups: placebo or XW10172 MR. The drug will be taken orally at bedtime for 6 weeks of treatment that will consist of a 2-week dose escalation/titration period and a 4-week stable-dose maintenance period. There will be a 2-week safety period following dosing.